Cargando…

Evaluation of respiratory rate monitoring performance using a home oxygen monitoring device among patients with interstitial lung disease and chronic obstructive pulmonary disease

BACKGROUND: Home monitoring devices have been developed to measure adherence to home oxygen therapy. In this study, we evaluated the performance of TeleOx(®), a commercially available remote monitoring device, in comparison with polysomnography (PSG) in patients with interstitial lung disease (ILD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Satoshi, Handa, Tomohiro, Tanabe, Naoya, Sato, Susumu, Tanizawa, Kiminobu, Sato, Atsuyasu, Morita, Satoshi, Chin, Kazuo, Hirai, Toyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007031/
https://www.ncbi.nlm.nih.gov/pubmed/35494164
http://dx.doi.org/10.36141/svdld.v39i1.12133
Descripción
Sumario:BACKGROUND: Home monitoring devices have been developed to measure adherence to home oxygen therapy. In this study, we evaluated the performance of TeleOx(®), a commercially available remote monitoring device, in comparison with polysomnography (PSG) in patients with interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) and the factors that affected TeleOx(®) correct use. METHODS: TeleOx(®) was connected on the patient or concentrator side. The oxygen flow rates were set at 1, 3, and 5 L/min. Intraclass correlation coefficient (ICC) (2,1) was used to determine the agreement between respiratory rate measured using TeleOx(®) and that measured using PSG, and the minimum acceptable level of reliability was >0.7. RESULTS: In total, 22 patients (16 with ILD and 6 with COPD) were assessed. In patients with ILD, the detection rate of patients’ respiration assessed using TeleOx(®) did not change according to the device’s position. It increased from 53.5% to 79.0% by changing the position from the concentrator to the patient side in patients with COPD. The ICC (2,1) value indicated that TeleOx(®) had acceptable reliability at oxygen flow rates of 1 and 3 L/min regardless of the device’s position in patients with ILD (the concentrator side: 0.9 and 0.82, respectively; the patient side: 0.95 and 0.82, respectively), whereas that did only at the oxygen flow rate of 1 L/min and in connecting TeleOx(®) on the patient side in patients with COPD (0.73). CONCLUSION: The monitoring performance of TeleOx(®) differed according to its position, oxygen flow rates, and patients’ diseases.